What benchmarks should be adopted for testing new methods before they are put to use with humans, and who should make such decisions?
B.
What level of antecedent evidence is necessary to justify translating preclinical research into work with human subjects?
C.
When contemplating testing new methods in people who have brain disorders and diseases, what is the best way to balance decision-making between the patient and legal surrogate in deciding on an acceptable level of risk?
D.
Can we maintain social justice when new expensive drugs and therapies are discovered and used in patients with neurodegenerative diseases?